









시장가
/
주식
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

133.600USD

+0.880+0.66%

시장 운영 시간 （ET）시세는 15분 지연됩니다

2.58B시가총액

손실P/E TTM



Ligand Pharmaceuticals Inc

133.600

+0.880+0.66%

개요 회사 금융

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

회사 정보

종목 코드 LGND

회사 이름Ligand Pharmaceuticals Inc

상장일Nov 18, 1992

CEOMr. Todd C. Davis

직원 수68

유형Ordinary Share

회계 연도 종료Nov 18

주소555 Heritage Drive, Suite 200

도시JUPITER

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호33458

전화18585507500

웹사이트https://www.ligand.com/

종목 코드 LGND

상장일Nov 18, 1992

CEOMr. Todd C. Davis

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

+14.86%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.29K

+31.26%

Mr. Todd C. Davis

Chief Executive Officer, Director

이름

이름/직위

직위

주식 보유

변동

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

주주

비율

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

주주 유형

주주

비율

Investment Advisor

57.94%

Investment Advisor/Hedge Fund

37.89%

Individual Investor

2.39%

Research Firm

1.84%

Pension Fund

1.60%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.28%

Hedge Fund

0.05%

Insurance Company

0.03%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

534

19.71M

102.14%

-793.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

2023Q1

528

16.47M

96.50%

-1.33M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

2.67M

13.86%

-26.33K

-0.97%

Mar 31, 2025

The Vanguard Group, Inc.

2.05M

10.63%

-29.89K

-1.44%

Mar 31, 2025

Janus Henderson Investors

1.03M

5.33%

+12.53K

+1.23%

Mar 31, 2025

Macquarie Investment Management

906.23K

4.7%

+21.85K

+2.47%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

744.93K

3.86%

+21.91K

+3.03%

Mar 31, 2025

State Street Global Advisors (US)

727.13K

3.77%

-16.51K

-2.22%

Mar 31, 2025

Congress Asset Management Company, LLP

642.71K

3.33%

+21.23K

+3.42%

Mar 31, 2025

Stephens Investment Management Group, LLC

607.22K

3.15%

-5.56K

-0.91%

Mar 31, 2025

Chicago Capital, LLC

554.52K

2.87%

+2.93K

+0.53%

Mar 31, 2025

Geode Capital Management, L.L.C.

464.45K

2.41%

+26.01K

+5.93%

Mar 31, 2025